HKAM
CYCN icon

Horizon Kinetics Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

Horizon Kinetics Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,667
Closed -$194K – 412
2020
Q1 		$194K Sell
3,667
-2,799
-43% -$200K 0.01% 321
2019
Q4 		$352K Buy
+6,466
New +$604K 0.01% 289

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horizon Kinetics Asset Management's CYCN Position: Q2 2020 in Review

Horizon Kinetics Asset Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 3,667 shares — an estimated $194K sold.

Horizon Kinetics Asset Management first reported a position in CYCN in Q4 2019 and held it in 2 quarters. The position peaked at $352K in Q4 2019. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • Horizon Kinetics Asset Management reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Horizon Kinetics Asset Management sold 3,667 Cyclerion Therapeutics shares in Q2 2020, an estimated $194K.
  • Horizon Kinetics Asset Management first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 2 quarters.
  • Horizon Kinetics Asset Management's Cyclerion Therapeutics position peaked at $352K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.